Xcout Intel
Bavarian Nordic competitors & alternatives
The 12 closest competitors and alternatives to Bavarian Nordic among biotech companies — ranked by similarity to what Bavarian Nordic actually does, not by market-cap band.
Subscribe to see Bavarian Nordic’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Bavarian Nordic
Bavarian Nordic A/S is a fully integrated biotechnology company focused on the research, development, and manufacturing of life-saving vaccines. The company serves healthcare professionals, patients, and global markets by delivering innovative vaccine products and solutions.
Bavarian Nordic at a glance
Bavarian Nordic is a biotech company headquartered in United Kingdom. Xcout tracks 15 named people at Bavarian Nordic, including Paul Chaplin (President & CEO). Xcout recorded 27 job postings from Bavarian Nordic in the last 90 days.
Bavarian Nordic leadership
- Paul ChaplinPresident & CEO
- Russell ThirskExecutive Vice President, Chief Operating Officer
- Henrik JuuelExecutive Vice President, Chief Financial Officer
- Jean-Christophe MayExecutive Vice President, Chief Commercial Officer
- Anne Louise EberhardMember of the board and chair
- Heidi HunterMember of the board and vice chair
9 more named people on record for Bavarian Nordic, with roles, board committees and tenure — see the full roster →
Hiring at Bavarian Nordic
Xcout recorded 27 job postings from Bavarian Nordic in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see Bavarian Nordic's hiring signals →
Top 12 Bavarian Nordic competitors
Ranked by semantic similarity — how close each company is to Bavarian Nordic by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
BioNTech is a global immunotherapy company that researches and develops mRNA vaccines and other treatments for cancer and infectious diseases. The company serves patients, healthcare professionals, and researchers by advancing scientific innovations into clinical therapies.
Similar biotech company
Panacea Biotec Limited is a pharmaceutical and biotechnology company engaged in research, development, and manufacturing of vaccines and pharmaceutical formulations.
Similar biotech company
BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company primarily engaged in the development of innovative vaccine platforms targeting both antiviral diseases and various forms of cancer. Its product pipeline features several key candidates, including two SARS-CoV-2 vaccines: BVX-0320, a monovalent version, and BVX-0121, a multivalent option. In the oncology space, BioVaxys is advancing BVX-0918A, a haptenized tumor cell vaccine designed for ovarian cancer, and BVX-0918C, aimed at cervical cancer. The company also has programs addressing Human Papillomavirus (HPV), such as Papilocare for HPV-dependent cervical lesions and the BVX-0204 HPV viral vaccine. Furthermore, BioVaxys offers CoviDTH, an immunodiagnostic tool developed to detect immune system responses in individuals previously exposed to SARS-CoV-2. To support its development initiatives, BioVaxys has established several strategic collaborations. It holds a bioproduction agreement with WuXi Biologics Limited for the manufacturing of SARS-CoV-2 s-proteins, crucial components for BVX-0320 and CoviDTH. The company also has a research collaboration for BVX-0320 with The Ohio State University, Wexner School of Medicine. Additionally, Bioanalytical Systems, Inc. is conducting preclinical toxicology studies for BioVaxys' CoviDTH immunodiagnostic under a separate agreement. The company's operations are headquartered in Vancouver, Canada.
Biotechnology
BiondVax Pharmaceuticals Ltd. is an Israeli biotechnology company developing vaccines and immunotherapies, best known for its M-001 universal influenza vaccine candidate designed to provide broad protection against multiple influenza strains. It has also pursued COVID-19 and other infectious-disease-related therapeutic programs, serving pharmaceutical and healthcare markets rather than individual consumers.
Similar biotech company
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Biotechnology
Valneva SE is a specialty vaccine company registered in Saint-Herblain, France, developing, producing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States.
Similar biotech company
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
Biotechnology
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Similar biotech company
Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The company's pipeline features several promising candidates, including SCIB1, currently in Phase II clinical trials for metastatic melanoma; SCIB2, aimed at non-small cell lung cancer; and Modi-1, which is undergoing Phase I/II studies for various indications such as head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is advancing Modi-2, a therapeutic agent specifically designed to target homocitrullinated cancer antigens. Its development efforts also encompass SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine engineered to provide protection against the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.
Biotechnology
AstraZeneca is an innovative biopharmaceutical company that researches, develops, and manufactures modern medicines for patients. It addresses major medical challenges across therapeutic areas such as oncology, cardiovascular and metabolic diseases, respiratory conditions, and immunology.
Similar biotech company
Bharat Biotech is a pioneering biotechnology company headquartered in Hyderabad, India. It is known for its world-class R&D and manufacturing capabilities, with a mission to deliver affordable, safe vaccines and bio-therapeutics.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Bavarian Nordic and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Bavarian Nordicand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →